Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX

In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly reduced risk of progression/death versus lenalidomide/dexamethasone alone in relapsed/refractory multiple myeloma. We provide one additional year of follow up and include the effect on minimal residual disease and in clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Dimopoulos, Meletios A., San-Miguel, Jesus, Belch, Andrew, White, Darrell, Benboubker, Lotfi, Cook, Gordon, Leiba, Merav, Morton, James, Ho, P. Joy, Kim, Kihyun, Takezako, Naoki, Moreau, Philippe, Kaufman, Jonathan L., Sutherland, Heather J., Lalancette, Marc, Magen, Hila, Iida, Shinsuke, Kim, Jin Seok, Prince, H. Miles, Cochrane, Tara, Oriol, Albert, Bahlis, Nizar J., Chari, Ajai, O’Rourke, Lisa, Wu, Kaida, Schecter, Jordan M., Casneuf, Tineke, Chiu, Christopher, Soong, David, Sasser, A. Kate, Khokhar, Nushmia Z., Avet-Loisea, Hervé, Usmani, Saad Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269302/
https://www.ncbi.nlm.nih.gov/pubmed/30237262
http://dx.doi.org/10.3324/haematol.2018.194282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269302/
https://www.ncbi.nlm.nih.gov/pubmed/30237262
http://dx.doi.org/10.3324/haematol.2018.194282

Ejemplares similares